secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0001559053-22-000049
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena earns $40M milestone from Novo Nordisk for ATTR cardiomyopathy drug advance
--------------------------------------------------------------------------------

- $40 million milestone payment from Novo Nordisk triggered by continued Phase 2 study of NNC6019 for ATTR cardiomyopathy.
- Total potential milestone payments up to $1.2 billion; $100 million earned to date including this payment.
- Novo Nordisk acquired full worldwide rights to ATTR amyloidosis pipeline from Prothena in July 2021.
- Phase 2 study addresses high unmet need in moderate to advanced ATTR amyloidosis with risk of early mortality.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000049/0001559053-22-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000049/prta-20221121.htm
  HTML page:      https://secwatch.observer/filing/0001559053-22-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer